Phase II trial of mitoqauzone in malignant primary brain tumors

Lynn G Feun, W. K A Yung, D. J. Stewart, Niramol Savaraj, G. P. Bodey

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Sixteen patients with primary malignant brain tumors, recurrent or progressive after surgery and radiation therapy, were treated with mitogauzone. Starting dose was 500 mg/m2 iv on a weekly schedule. In 15 evaluable patients no tumor regressions were observed. Four patients had stabilization of disease.

Original languageEnglish
Pages (from-to)329-330
Number of pages2
JournalCancer Treatment Reports
Volume69
Issue number3
StatePublished - Jul 24 1985
Externally publishedYes

Fingerprint

Brain Neoplasms
Appointments and Schedules
Radiotherapy
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Feun, L. G., Yung, W. K. A., Stewart, D. J., Savaraj, N., & Bodey, G. P. (1985). Phase II trial of mitoqauzone in malignant primary brain tumors. Cancer Treatment Reports, 69(3), 329-330.

Phase II trial of mitoqauzone in malignant primary brain tumors. / Feun, Lynn G; Yung, W. K A; Stewart, D. J.; Savaraj, Niramol; Bodey, G. P.

In: Cancer Treatment Reports, Vol. 69, No. 3, 24.07.1985, p. 329-330.

Research output: Contribution to journalArticle

Feun, LG, Yung, WKA, Stewart, DJ, Savaraj, N & Bodey, GP 1985, 'Phase II trial of mitoqauzone in malignant primary brain tumors', Cancer Treatment Reports, vol. 69, no. 3, pp. 329-330.
Feun, Lynn G ; Yung, W. K A ; Stewart, D. J. ; Savaraj, Niramol ; Bodey, G. P. / Phase II trial of mitoqauzone in malignant primary brain tumors. In: Cancer Treatment Reports. 1985 ; Vol. 69, No. 3. pp. 329-330.
@article{890d1a928c2d49bd861dddfcbcea920f,
title = "Phase II trial of mitoqauzone in malignant primary brain tumors",
abstract = "Sixteen patients with primary malignant brain tumors, recurrent or progressive after surgery and radiation therapy, were treated with mitogauzone. Starting dose was 500 mg/m2 iv on a weekly schedule. In 15 evaluable patients no tumor regressions were observed. Four patients had stabilization of disease.",
author = "Feun, {Lynn G} and Yung, {W. K A} and Stewart, {D. J.} and Niramol Savaraj and Bodey, {G. P.}",
year = "1985",
month = "7",
day = "24",
language = "English",
volume = "69",
pages = "329--330",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Phase II trial of mitoqauzone in malignant primary brain tumors

AU - Feun, Lynn G

AU - Yung, W. K A

AU - Stewart, D. J.

AU - Savaraj, Niramol

AU - Bodey, G. P.

PY - 1985/7/24

Y1 - 1985/7/24

N2 - Sixteen patients with primary malignant brain tumors, recurrent or progressive after surgery and radiation therapy, were treated with mitogauzone. Starting dose was 500 mg/m2 iv on a weekly schedule. In 15 evaluable patients no tumor regressions were observed. Four patients had stabilization of disease.

AB - Sixteen patients with primary malignant brain tumors, recurrent or progressive after surgery and radiation therapy, were treated with mitogauzone. Starting dose was 500 mg/m2 iv on a weekly schedule. In 15 evaluable patients no tumor regressions were observed. Four patients had stabilization of disease.

UR - http://www.scopus.com/inward/record.url?scp=0021824525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021824525&partnerID=8YFLogxK

M3 - Article

C2 - 3978660

AN - SCOPUS:0021824525

VL - 69

SP - 329

EP - 330

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

ER -